Values and preferences in COVID-19 public health guidelines: A

systematic review

1

2

3 Sarah Kirsh 4 Departments of Anesthesia and Health Research Methods, Evidence, and Impact 5 McMaster University, Hamilton, ON 6 Michael Ling 7 Departments of Anesthesia 8 McMaster University, Hamilton, ON 9 Tanvir Jassal 10 Departments of Anesthesia McMaster University, Hamilton, ON 11 12 Tyler Pitre 13 Division of Respirology, Department of Medicine 14 University of Toronto 15 **Thomas Pigott** 16 Department of Health Research Methods, Evidence, and Impact 17 McMaster University, Hamilton, ON 18 Department of Family Medicine, 19 Queens University, Kingston, ON 20 Dena Zeraatkar* 21 Departments of Anesthesia and Health Research Methods, Evidence, and Impact 22 McMaster University, Hamilton, ON 23 24 *Corresponding author: 25 Disclaimers: None. 26 Funding: None. 27 Data: We will make all data publicly accessible upon the publication of this manuscript on Open Science Framework (https://osf.io/aup36/). 28 29 Acknowledgements: None. 30 Authors' Contributions: DZ conceived the idea. SK, ML, and TJ collected data. SK and ML synthesized 31 data and produced descriptive characteristics. SK, TP, and DZ wrote the first draft of the manuscript. All 32 authors reviewed, provided critical feedback on the manuscript, and approved the final version of the 33 manuscript. 34 35 Word count: 4,975 36 Tables: 3 37 Figures: 2

40

41

42

43

44 45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61 62

63

64

Abstract Background: Internationally accepted standards for trustworthy guidelines include the necessity to ground recommendations in values and preferences. Considering values and preferences respects the rights of citizens to participate in health decision-making and ensures that guidelines align with the needs and priorities of the communities they are intended to serve. Early anecdotal reports suggest that COVID-19 public health guidelines did not consider values and preferences. Objective: To capture and characterize whether and how COVID-19 public health guidelines considered values and preferences. Methods: We performed a systematic review of COVID-19 public health guidelines. We searched the eCOVID19 RecMap platform—a comprehensive international catalog of COVID-19 guidelines—up to July 2023. We included guidelines that made recommendations addressing vaccination, masking, isolation, lockdowns, travel restrictions, contact tracing, infection surveillance, and school closures. Reviewers worked independently and in duplicate to review guidelines for consideration of values and preferences. Results: Our search yielded 129 eligible guidelines, of which 43 (33.3%) were published by national organizations, 73 (56.6%) by international organizations, and 14 (10.9%) by professional societies and associations. Twenty-six (20.2%) guidelines considered values and preferences. Among guidelines that considered values and preferences, most did so to assess the acceptability of recommendations (23; 88.5%) and by referencing published research (24; 92.3%). Guidelines only occasionally engaged laypersons as part of the guideline development group (6; 23.1%). None of the guidelines performed systematic reviews of the literature addressing values and preferences. Conclusion: Most COVID-19 public health guidelines did not consider values and preferences. When values and preferences were considered, it was suboptimal. Disregard for values and preferences in guidelines might have partly contributed to divisive and unpopular COVID-19 policies. Given the possibility of future health emergencies, we recommend guideline developers identify efficient methods for considering values and preferences in crisis situations.

Background

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

values and preferences, leaving some uncertainty.

Public health guidelines provide recommendations intended to optimize population health (1). They are typically published by professional associations and authoritative organizations, examples of which include the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC). The impact of public health guidelines is wide-reaching and diverse—they inform national policies, rules and regulations at schools and workplaces, and messaging to which the public is exposed. Given their significant impact, it is essential for these guidelines to be credible and effective. For guidelines to be considered credible, they must adhere to certain standards (2-12). Considering public values and preferences—defined as the public's perspectives, beliefs, expectations, and goals for health and life—is internationally recognized as a critical component of credible guideline development (2, 3, 10). Considering values and preferences respects the rights of citizens to participate in health decision-making, aligns guidelines with the needs and priorities of the communities they are intended to serve, ensures recommendations are logistically feasible and acceptable, and improves support for the recommendations (13, 14). Values and preferences may vary by country or setting, and therefore may be an important lens for contextualizing or adapting guidance between settings (15). While some public health professionals and decision-makers may argue that scientific evidence alone should inform recommendations, trustworthy guideline development necessitates the synthesis of both scientific evidence and values and preferences to arrive at recommendations (2, 3, 10). Guideline developers face decisions that invariably involve trade-offs between benefits and harms. For example, a new lung cancer screening program might improve survival rates through early detection but could also result in overdiagnosis, false positives, radiation, and divert resources from other healthcare services, potentially increasing morbidity and mortality from other causes. Ideally, the public's values and preferences should guide the assessment of whether the benefits of a given action outweigh its harms. For these reasons, nearly all organizations that establish standards for guideline development advise that guidelines also consider values and preferences (2, 3, 10, 16). For example, the AGREE II tool, the gold standard tool for evaluating the quality of guidelines, includes a domain addressing the consideration of values and preferences (3). Likewise, the GRADE Evidence-to-Decision frameworks, the most commonly used frameworks for formulating recommendations, include values and preferences as a key consideration (10). Guideline developers may incorporate public values and preferences in several ways, such as involving laypersons as part of the guideline development group, reviewing published research on public values and preferences, conducting de novo studies, and providing the public the opportunity to comment on draft recommendations (2, 3, 10, 14, 17-22). Ideally, guideline developers should perform systematic reviews of the literature addressing values and preferences (19, 23, 24). In situations in which guideline developers are unable to find sufficient high-quality evidence, they can perform de novo surveys and focus groups to generate this information. While insights and beliefs of the guideline development group, especially if it includes laypersons, are valuable, they may not fully capture the broader public's

104

105106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133134

135

136

137

138

139

140

141

The COVID-19 pandemic caused significant threats to health globally. In response, governments implemented policies, informed by public health guidelines, that ranged from stringent measures to curb transmission, including "lockdowns", to attempts that focused on minimizing disruptions to daily life (25-28). Public health professionals, and ultimately politicians, were confronted with the delicate, ethically complex task of balancing COVID-19 with other public health problems and social and economic well-being. Ideally, public values and preferences should have informed this trade-off. Early anecdotal reports, however, suggest that public engagement was limited and suboptimal in COVID-19 public health guidelines (29). In France, for example, the public was not consulted about lockdowns (30). In Germany, early decisions were made only by a handpicked group of scientific experts (31, 32). While rigorous guidelines that considered values and preferences may have been possible, the unprecedented circumstances posed by the COVID-19 pandemic may have adversely impacted guideline development methods and thus guideline quality. Nevertheless, consideration of values and preferences remains important even in crisis situations (33, 34). Even guidance for producing guidelines during emergency situations requires consideration of values and preferences (33). Suboptimal consideration of values and preferences might have contributed to divisive and unpopular policies, the erosion of trust in public health, and limited compliance (35-40). As the pandemic evolves from an acute threat to a long-term public health challenge, now is a critical time to evaluate and learn from our response. While the COVID-19 pandemic was unprecedented, we anticipate other health emergencies that will also benefit from credible guidelines that are aligned with societal values. We conducted a systematic review of national and international public health COVID-19 guidelines to capture and characterize whether and how they considered public values and preferences. Methods We report our systematic review of COVID-19 public health guidelines following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines for systematic reviews (41). Figure 1 presents an overview of our methods. Search strategy and screening We intended to include a representative sample of national and international COVID-19 public health guidelines. We anticipated that a search of research databases would identify few eligible guidelines, since most guidelines are typically published on webpages or reports from national and professional organizations instead of journals. Thus, to identify eligible guidelines, we searched the eCOVID19-19 RecMap—a comprehensive open-access digital collection of COVID-19 guidelines and recommendations, developed in collaboration between Cochrane Canada, the WHO Collaborating Center for Infectious Diseases, and the Guidelines International Network, up to July 2023 (42, 43). The eCOVID19-19 RecMap presents thematically organized lists of recommendations contained in COVID-19 guidelines. Following training and calibration to ensure sufficient agreement, two reviewers worked independently and in duplicate to screen all recommendations catalogued in the eCOVID19 RecMap for eligibility. When reviewers identified an eligible recommendation, they included the guideline containing that recommendation in the present systematic review. Reviewers resolved discrepancies by discussion, or when necessary, by adjudication with a third reviewer.

We supplemented our search by reviewing webpages of national and international guideline producing organizations (i.e., WHO, US CDC, and European Centers for Disease Control) and reviewing the references of the included guidelines.

Eligibility criteria

We included national and international guidelines that contained one or more COVID-19 public health recommendations. We defined guidelines as documents that described themselves as 'guidelines' or as providing recommendations. Distinguishing between clinical practice and public health guidelines is challenging and guidelines may include a combination of clinical practice and public health recommendations. To address this issue, we pragmatically defined public health recommendations as recommendations addressing interventions aimed at the population level instead of at the individual patient level or recommendations that are motivated by population effects (e.g., staying home when sick to prevent spread of COVID-19, lockdowns, closure of educational institutions).

We recognized that not all recommendations will require consideration of values and preferences. For example, the benefits of a particular course of action may obviously and overwhelmingly outweigh potential harms, or vice versa, such that the consideration of values and preferences is unimportant (44, 45). For example, the potential benefits of hand washing overwhelmingly outweigh any potential harms such that a recommendation to practice frequent handwashing does not require consideration of values and preferences. We restricted eligibility to guidelines that made recommendations addressing topics that we considered to be sensitive to values and preferences: vaccination, masking, isolation, lockdowns, travel restrictions, contact tracing, infection surveillance, and school closures. Our selection of these topics was informed by scientific discourse and discussions in social and traditional media. Box 1 describes how recommendations addressing these topics are sensitive to values and preferences.

Box 1: Description of the ways in which recommendations addressing select topics require consideration of values and preferences

<u>Recommendations addressing vaccination</u> will require weighing the benefits of vaccination such as prevention of COVID-19 adverse health outcomes against its adverse effects, like myocarditis and blood clots. While this may be straightforward with older or medically fragile populations, it is more nuanced for younger populations who are at lower risk of COVID-19 complications (46).

<u>Recommendations addressing isolation, lockdowns, and other infection control measures</u> necessitate weighing immediate benefits of reducing transmission against broader health, social, and economic consequences (47, 48).

Recommendations addressing closure of educational institutions must weigh educational achievement and the social value of schooling against the goal of reducing community COVID-19 transmission (49, 50).

<u>Surveillance and contact tracing</u> must balance the advantage of preventing COVID-19 transmission against individual privacy rights, medical confidentiality, and potential data breaches (49-51).

For feasibility, we excluded regional guidelines. We also excluded guidelines addressing the care of patients with COVID-19, the operation of healthcare facilities, performance of diagnostic tests for COVID-19, care of patients with comorbidities during the pandemic, management of long covid, and niche professional activities (e.g., care of heritage collections during COVID-19).

When guidelines were updated, resulting in multiple versions, we included all versions in our study. This approach allowed us to study how consideration of values and preferences may have evolved during the course of the pandemic.

Data extraction

Following training and calibration to ensure sufficient agreement, two reviewers worked independently and in duplicate and used a pilot-tested structured form to collect information on guideline characteristics, methods, and values and preferences.

We intended to capture whether and how guidelines considered public values and preferences. We used a broad operationalization of values and preferences, defined as public's perspectives, beliefs, expectations, and goals for health and life, including but not limited to soliciting insights from laypersons as part of the guideline development process or as part of the dissemination process, assessing acceptability and tolerability of potential courses of action, and weighing benefits and harms (2, 3, 10).

The Armstrong framework for patient engagement in guideline development informed the type of data that we collected (18). This framework contains 10 categories describing the steps of the guideline development process in which values and preferences may be considered, 37 categories describing the purpose of considering values and preferences, and 36 categories describing methods by which values and preferences may be considered (18). Box 2 presents an overview of the framework. While this framework was originally conceived for patient engagement in clinical practice guidelines, our examination suggests it is also equally relevant for public health guidelines. We created new categories when we encountered scenarios not included in the framework.

Box 2: Overview of the Armstrong framewo categories (18)	rk for patient engagement in guidelines with example
Values & preferences	Example categories
Step in guideline development process in	- Nominating guideline topics
which values and preferences may be	- Developing recommendations
considered	 Disseminating and implementing
	recommendations
Purpose of considering values and	- Identify topics that are important to patients,
preferences	caregivers, and the community
	- Assist in translating evidence-based conclusions
	into meaningful, clear, and respectful
	recommendations
	- Endorse guidelines from patient perspective
Methods for considering values and	- Solicit topic nominations from public
preferences	- Review existing research on patients'

190

191

192193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

preferences Consult patients, caregivers, and advocacy groups regarding barriers to dissemination and implementation For guidelines published in a language other than English, we intended to use Google Translate to translate the guideline document to facilitate extraction and subsequently ask a native language speaker to confirm our extractions. We did not, however, identify any eligible guidelines published in a language other than English. Reviewers resolved discrepancies by discussion, and, if necessary, by adjudication with a third reviewer. Data synthesis and analysis Descriptive statistics summarize guideline characteristics, methods, and consideration of values & preferences. We used content analysis to map the steps in which values and preferences were considered in guideline development, the purpose for considering values and preferences, and methods for considering values and preferences to the categories in the Armstrong framework (18). We anticipated that consideration of values and preferences across guidelines may differ according to the time at which they were published, the topics they address, the jurisdiction of the guideline (high income versus low/middle income countries), the publishing organization, and whether the guideline used GRADE methods (52). Hence, we also interpret results considering these characteristics. Results Search results We reviewed 617 guidelines for eligibility, of which 129 proved eligible. Figure 2 presents the selection of guidelines. Supplement 1 lists included guidelines and Supplement 2 lists the excluded guidelines and reasons for their exclusion. **Guideline characteristics** Of 129 included guidelines, 73 (56.6%) were published by international organizations, 43 (33.3%) by national organizations, and 14 (10.9%) by professional societies and associations. We included guidelines from a total of 25 unique government and non-government organizations. Forty (31%) guidelines were published in 2020, 48 (37.2%) in 2021, 33 (25.6%) in 2022 and 8 (6.2%) in 2023. Nearly all guidelines targeted high-income countries or regions (96.9%), typically in North America or Europe. Guidelines seldom disclosed funding (24; 18.6%) or conflicts of interest (35; 27.1%). Five (3.9%) guidelines were updates of previously published guidelines. Less than one in 10 guidelines used GRADE to evaluate the certainty of evidence (52). An almost equal proportion used GRADE evidence-to-decision frameworks to formulate recommendations (10). Guidelines addressed a range of topics, with the most common topics being vaccination and vaccine prioritization (36; 27.9%), general public health measures (34; 26.4%), and infection control & prevention (18; 14%). Most guidelines included recommendations that targeted community-dwelling

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252253

254

255

256

257

people (42; 32.6%) or were intended to be used by public health practitioners and other decisionmakers (59; 45.7%). Values and preferences Of 129 eligible guidelines, 26 (20.2%) considered values and preferences. Seventeen of these guidelines (65.4%) were published by the WHO, 7 (26.9%) by the CDC, and 1 (3.8%) by the American College of Obstetricians and Gynecologists. Six (23.1%) of the guidelines were iterations of the WHO living guideline on infection prevention and control (53-58). None of the guidelines were published in 2020, 8 (30.8%) were published in 2021, 13 (50%) in 2022, and four (15.4%) in 2023. Nearly all guidelines (22; 84.6%) that considered values and preferences also used GRADE methods to evaluate the certainty of evidence and to move from evidence to recommendations. Guidelines addressed either vaccination and vaccine prioritization (16; 61.5%), masking in the community (6; 23.1%), or school & education (2; 7.7%). Table 2 describes the consideration of values and preferences in guidelines and table 3 describes the guidelines that considered values and preferences. Among guidelines that considered values and preferences, all did so to develop recommendations. Half of these guidelines also recommended for consideration of values and preferences in the implementation of recommendations (11; 42.3%). None of the guidelines considered values in preferences in other steps of the guideline development process, such as nominating or prioritizing topic, drafting recommendations, or disseminating or endorsing the guideline. The purpose for considering values and preferences was most often to assess the acceptability of recommendations (23; 88.5%) or to weigh anticipated benefits and harms of alternative courses of action (15; 57.7%). None of the guidelines reported considering values and preferences for other purposes, like developing simple language summaries of the recommendations. Most guidelines considered values and preferences by consulting published survey research (24; 92.3%). These guidelines did not report identifying this published research using systematic review methods. None of the guidelines performed de novo research or provided opportunity for public comment. Supplement 3 lists the studies referenced by guidelines as evidence of values and preferences. Less than a quarter of guidelines (6; 23.1%) reported engaging lay persons as part of the guideline development group. Among guidelines that reported engaging lay persons as part of the guideline development group, none described the number of lay people consulted or their demographic characteristics (e.g., age, sex, equity deserving characteristics). A minority of guideline development groups (6; 23.1%) reported making assumptions about public values and preferences. A minority of guidelines (5; 19.2%) reported consulting with professional associations about values and preferences. Among guidelines that were updated throughout the course of the pandemic, we did not identify any guidelines in which values and preferences were first not considered but were later incorporated in subsequent updates.

- None of the guidelines reflected on lessons learned or the advantages or disadvantages of considering
- public values and preferences or evaluated the quality or impact of public engagement.
- Box 3 describes examples of ways in which guidelines considered values and preferences.

Box 3: Examples of ways in which values & preferences informed recommendations Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline (57)

A guideline by the WHO addressed infection prevention and control interventions (57). The guideline was initially published in 2021, and updated five times (53-58). The guideline made recommendations regarding masking by children and adults in the community and in healthcare settings. For the purposes of this study, we focused on recommendations for community settings.

The guideline used GRADE evidence-to-decision frameworks to formulate recommendations, which involves consideration of the magnitude of benefits and harms, values and preferences, resources, equity, feasibility, and acceptability.

For children under five in the community, the guideline made a conditional recommendation against masks. The guideline reports that recommendations addressing mask use in children were informed by consultations with the United Nations Children's Fund (UNICEF), the International Pediatric Association (IPA), and pediatric health professionals from different geographical regions, regarding children's experiences with masks. It can be assumed that these consultations informed considerations of values and preferences.

In considering values and preferences, the guideline development group noted that there is substantial variability. The guideline did not cite any published studies supporting judgments about values and preferences nor did it describe any de novo studies performed by the guideline development group to inform recommendations. The guideline development group also noted that there is a lack of evidence as to the acceptability of mask use for children in this age group. The guideline cited two studies supporting the acceptability of masking in children. The first study described adherence to masking in pre-K, kindergarten, first, or second grades in Atlanta (59). The second study evaluated mothers' perceptions of masking in children in Nigeria (60).

The guideline made a strong recommendation for mask use for adults in the community in crowded spaces, following a recent exposure, when sharing a space with a person who displays signs or symptoms of COVID-19, and for people at high risk of severe COVID-19 complications.

For this recommendation, values and preferences were informed by collective input and experience of the guideline development group, which comprised members (including laypersons in the community, clinicians, and policymakers) who represented all WHO regions and ranged from low to high-income countries, supplemented by key studies suggested by guideline development group members when available. The guideline did not describe the number of laypersons involved nor their demographic characteristics. The guideline development group assumed that there would be a general preference towards mask use in the community, though values and preferences are likely to vary, and those at higher risk of COVID-19 complications might perceive the benefits of mask use to

be greater compared to other individuals.

The guideline development group also considered acceptability of masks and noted that members of the public may not deem mask use as an acceptable public health intervention. The guideline group cited three studies to support their judgment (61-63), one of which addressed socio-behavioral factors that predict adherence to masks (62) and a review of qualitative studies of the social meaning assigned to masking (63).

Recommendations from the WHO Technical Advisory Group on Safe Schooling During the COVID-19 Pandemic (64)

Another guideline by the WHO addressed schooling during the COVID-19 pandemic (64). The guideline was developed by a WHO Technical Advisory Group that comprised a range of stakeholders, including young people. The guideline made a recommendation to actively involve children and adolescents in decision-making regarding schooling. The guideline, however, did not describe the number of young people, the countries from which they were recruited, their age, and demographic characteristics, and the purpose for which values and preferences were considered.

The CDC Advisory Committee on Immunization Practices (ACIP) Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years (65)

A guideline by the CDC Advisory Committee on Immunization Practices (ACIP) makes a recommendation regarding the Moderna COVID-19 Vaccine (65). The guideline uses GRADE evidence-to-decision framework (called the evidence-to-recommendation framework) to arrive at a recommendation. The evidence-to-decision framework includes consideration of values and preferences, as well as other factors like feasibility, resource use, and equity. In considering values and preferences, the guideline references existing survey research that suggests that most US adults intend to be vaccinated against COVID-19 and vaccination rates following the approval of the Pfizer-BioNTech COVID-19 vaccine. The guideline development group noted variability and uncertainty in how all populations value the vaccine. For example, most surveys used convenience sampling, had limited representation of minority populations, and low or unknown response rates.

Discussion

261

262

263

264

265

266

267

268

269

270

271

Main findings

Our systematic review of 129 COVID-19 public health guidelines found that they seldom considered values and preferences. Among the few guidelines that considered values and preferences, we found limitations in how they were considered. For example, none of the included guidelines performed or referenced systematic reviews of values and preferences. Instead, they referenced select research publications without a description of how the studies were identified. Failure to perform systematic reviews risks cherry-picking studies based on their findings. Some guideline development groups made assumptions about the public's values and preferences. This approach, though practical, may be suboptimal because the general public likely weighs pandemic policy decisions differently than professionals (31).

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290 291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

The pandemic forced guideline developers to produce guidelines quickly under circumstances that did not allow for typical guideline development procedures such as in-person meetings or travel. While the pressures of the pandemic may account for the suboptimal consideration of values and preferences, we show that even guidelines produced three years into the pandemic, when most of these challenges were mitigated and circumstances had normalized, did not consider values and preferences. Further, none of the guidelines explicitly acknowledged lack of or inadequate consideration of values and preferences, engagement of the public, or the use of pragmatic approaches as limitations. Thus, other factors are more likely to explain the suboptimal consideration of values and preferences. Until recently, there has been limited consensus on the ideal approaches to involve laypersons in guideline development (11, 22, 66). For example, while methodological handbooks strongly encourage consideration of values and preferences, they contain little practical guidance (12, 21, 22). Hence, even if guideline developers may have wished to incorporate values and preferences, they may have been uncertain about how to do so effectively. Adding to this already complex process is evidence that values and preferences related to COVID-19 recommendations varied widely across regions and age groups and changed during the pandemic (67-70). Such challenges might have discouraged guideline developers from giving priority to this issue. The omission of values and preferences could also be attributed to guideline developers' limited familiarity with established standards for developing trustworthy guidelines. This is further evidenced by additional methodological oversights in guidelines, such as the failure to disclose the conflicts of interests of the guideline development group. Moreover, a recent study also showed that few COVID-19 recommendations considered issues related to health equity—an aspect increasingly recognized as an important component of guideline development (71). Such patterns suggest that guideline developers that did not consider values and preferences might not be fully aware of established standards for trustworthy guideline development. Relation to previous research This review is the first to systematically examine how COVID-19 public health guidelines considered public values and preferences. Prior research on COVID-19 guideline quality has mainly focused on clinical practice guidelines (e.g., guidelines that advise healthcare providers on the treatment of patients with COVID-19) (29, 31, 72). Previous evidence on public engagement during COVID-19 has typically been in the form of anecdotal evidence and case studies (29, 31, 72). For example, the Scottish government hosted an online public discussion about people's ideas and concerns around lockdown, which generated 18,000 comments from citizens (73). In the Netherlands, 30,000 citizens advised the government on relaxing lockdown measures (31). Our work systematically evaluates how and to what extent COVID-19 guidelines accounted for public values and preferences. Strengths and limitation The strengths of this review include our systematic search for COVID-19 public health guidelines and rigorous collection of data on values and preferences by two reviewers independently using an established framework for consideration of values and preferences.

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

Although we attempted to provide a comprehensive overview of all COVID-19 public health guidelines, there remains a possibility that some eligible guidelines were excluded. We used the eCOVID-19 RecMap platform to identify guidelines—originally designed to reduce the time and resources organizations would need to invest to develop de novo guidelines and to facilitate guideline adaptation (42, 44, 45). Moreover, the eCOVID19 RecMap appears to favor guidelines from the most influential organizations that likely have the highest standards for developing guidelines (e.g., WHO, CDC). Consequently, our sample likely includes an overrepresentation of guidelines that consider values and preferences. Likewise, although we used a broad definition and operationalization of values and preferences, it is possible that our definition and framework may not have captured guideline developers' considerations of values and preferences (18). To identify eligible guidelines, reviewers worked independently and in duplicate to screen all recommendations catalogued on the eCOVID-19 RecMap. Any guideline that contained at minimum one eligible recommendation was included. Given the length and complexity of guideline documents, it is possible that we may have missed guidelines that included eligible recommendations. For feasibility, we restricted eligibility to national and international guidelines and excluded regional guidelines. It is possible for national and international guidelines to be adapted into regional settings during which local values and preferences may be considered. Guidelines are sometimes updated as new evidence emerges and a single guideline may include several versions. We intended to include all versions of guidelines to study how consideration of values and preferences may have evolved during the pandemic. It is possible that some organizations removed access to outdated guidelines or replaced outdated guidelines on webpages, precluding their inclusion in our study. It is possible that guidelines considered values and preferences but did not report on such considerations. For example, a survey of guideline developers showed that organizations often implicitly rather than explicitly consider values and preferences (66). Nevertheless, failure to explicitly report consideration of values and preferences reduces the guideline's transparency and leaves readers unable to evaluate its credibility. For select recommendations, such as good practice statements that summarize recommendations where the alternative would be absurd (e.g., a recommendation for surgeons to forego handwashing before a surgical procedure), values and preferences are unlikely to be consequential (44, 45). We, however, restricted our study to guidelines that addressed recommendations that require consideration of values and preferences. For example, recommendations addressing isolation, lockdowns, and other infection control measures necessitate weighing immediate benefits of controlling the virus against broader health and socioeconomic consequences (47, 48). We did not review documents from guideline producing organizations outlining their typical standards and methods for developing guidelines. We anticipated that these organizations may have diverged from typical practices due to the unique context presented by the COVID-19 pandemic. Likewise,

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380 381

382

383

384

inferences on how recommendations might have differed if values and preferences were considered were beyond the scope of this study. **Implications** As the pandemic evolves from an acute threat to a long-term public health issue, now is a critical time to reflect and learn from our response to inform future emergency preparedness efforts. While the COVID-19 pandemic was unprecedented, we anticipate other health emergencies that will also benefit from guidelines that are aligned with societal values. Our investigation revealed that few COVID-19 public health guidelines considered values and preferences, which may have contributed to unpopular pandemic policies and led to an erosion of trust in public health (35-38, 74-77). This erosion of trust may present a challenge for managing future crises, which may again require cohesive and coordinated efforts from the public. We acknowledge that guideline developers and decision-makers may be reluctant to consider values and preferences in favor of relying only on scientific evidence. Considering values and preferences respects the rights of citizens to participate in health decision-making, aligns guidelines with the needs and priorities of the communities they are intended to serve, ensures recommendations are logistically feasible and acceptable, and improves support for the recommendations (13, 14). Formulating recommendations will invariably involve inherent value judgements—alternative courses of action are almost always accompanied by both benefits and harms and value judgments are necessary to determine whether benefits of a particular course of action outweigh harms or vice versa. For these reasons, all guideline producing organizations and organizations that establish standards for developing guidelines require consideration of values and preferences (2, 3, 10, 16, 78). Our results suggest that guideline developers may not be aware of standards that necessitate consideration of values and preferences. Therefore, we recommend future efforts focus on improving guideline developers' understanding of the importance of values and preferences in formulating recommendations. Future research could also address guideline developers' experiences considering values and preferences in COVID-19 guidelines. Surveys and interviews with guideline developers can provide insights on facilitators and barriers to public engagement during the pandemic and identify efficient methods for considering values and preferences in health emergencies and crisis situations. Such research will ensure that future health crises are met with public health guidelines that are aligned with core societal values. Conclusion We reviewed a sample of COVID-19 public health guidelines to capture and characterize whether and how they considered public values and preferences. We found few COVID-19 public health guidelines to consider public values and preferences. Where values and preferences were considered, it was using suboptimal methods. Disregard for values and preferences might have contributed to divisive COVID-19 policies. While the COVID-19 pandemic was unprecedented, we anticipate other health emergencies that will also benefit from guidelines that are aligned with societal values. We recommend future

research identify efficient methods for considering values and preferences in health emergencies and crisis situations.

387 Tables

Table 1: Guideline characteristics			
Publisher		Topic	
Government organization	43 (33.3%)	Cultural practices in the context of COVID-19	2 (1.6%)
Professional association	14 (10.9%)	School and education	4 (3.1%)
International agency	73 (56.6%)	Lockdowns and isolation	5 (3.9%)
Region		Masking	10 (7.8%)
North America	44 (34.1%)	Vaccination & vaccine prioritization	36 (27.9%)
Europe	25 (19.4%)	General public health measures	34 (26.4%)
Asia	4 (3.1%)	Operation of healthcare facilities related to visitation	1 (0.8%)
Africa	0 (0%)	Contact tracing	6 (4.7%)
South America	0 (0%)	Infection control & prevention	18 (14.0%)
Oceania	1 (0.8%)	Travel	5 (3.9%)
International	55 (42.6%)	Testing for COVID-19	2 (1.6%)
Date of publication		Public health surveillance and response plan	6 (4.7%)
January to June 2020	23 (17.8%)	Target users	
July to December 2020	17 (13.2%)	Children	13 (10.1%)
January to June 2021	24 (18.6%)	Elderly	1 (0.8%)
July to December 2021	24 (18.6%)	Community-dwelling people	42 (32.6%)
January to June 2022	24 (18.6%)	Mothers and infants	2 (1.6%)
July to December 2022	9 (7%)	Refugees and asylum seekers	7 (5.4%)
January to June 2023	8 (6.2%)	Public health professionals and other decision- makers	59 (45.7%)
Funding		Staff	5 (3.9%)
Not reported	105 (81.4%)	Setting	
No funding	6 (4.7%)	Community	104 (80.6%)
Governmental support	6 (4.7%)	School/university/college	11 (8.5%)
Institutional support	15 (11.6%)	Healthcare facilities	8 (6.2%)
Private not-for-profit foundation	1 (0.8%)	Long term care facilities	2 (1.6%)
Disclosure of conflicts of interest		Detention center/homeless service sites	4 (3.1%)
Not reported	89 (69%)	GRADE methods	
None	23 (17.8%)	GRADE to evaluate the certainty of evidence	24 (18.6%)

Disclosed potential interests for one or more members involved with the development of the guideline	17 (13.2%)	GRADE to move from evidence to recommendations	23 (17.8%)
Methods to manage conflicts of interest		Did not use GRADE	104 (80.6%)
Not reported	94 (72.9%)		
Members of the guideline development group disclosed conflicts and none of the members of the guideline development group were deemed to have relevant conflicts	16 (12.4%)		
Members of the guideline development group disclosed conflicts and a member of the publishing organization reviewed and managed conflicts of interest	2 (1.6%)		
Members of the guideline development group disclosed conflicts and those with conflicts recused from formulating recommendation	14 (10.9%)		

Table 2: Description of the steps, purpose, and methods by which guidelines cor	nsidered values and					
preferences						
Step of the guideline development process in which values and preferences wer	e considered					
Developing recommendations	26 (100%)					
Recommend for consideration of values and preferences in implementation of	11 (42.3%)					
recommendations						
Purpose for considering of values and preferences						
Considering acceptability of recommendations	23 (88.5%)					
Weighing benefits and harms	15 (57.7%)					
Identifying barriers to implementation and possible solutions	1 (3.8%)					
Not reported	1 (3.8%)					
Methods to consider values and preferences						
Referenced existing survey research on values and preferences	24 (92.3%)					
Referenced existing interview research on values and preferences	1 (3.8%)					
Engaged lay persons as part of guideline development group	6 (23.1%)					
Guideline development group made assumptions about values and preferences 6 (23.1%)						
Consulted with professional associations	5 (19.2%)					
Not reported	1 (3.8%)					

medRxiv preprint doi: https://doi.org/10.1101/2024.03.25.24304859; this version posted March 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has graded medRxiga licease to display the genrint in pergetuity.

Table 3: Description of guidelines that considered values and preferences


Guideline title		Latest			Consideration of values and preferences		ices
	Publisher	update	Country	Topic	Step	Purpose	Methods
nterim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, une 2022 (79)	CDC	2022	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
OVID-19 immunization in refugees and migrants: rinciples and key considerations: interim guidance, 1 August 2021 (80)	WHO	2021	International	Vaccination & vaccine prioritization	Developing recommendations	Identify barriers to implementation and possible solutions	Referenced existing research on patients' preferences
OVID-19 Vaccination Considerations for Obstetric— iynecologic Care (81)	American College of Obstetricians and Gynecologists	2023	United States	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms	NR
uideline WHO Infection Prevention and Control OVID-19 Living Guideline - Mask use in community ettings (58)	WHO	2021	International	Masking	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences; Asked guideline development to make assumptions about preferences;
fection prevention and control in the context of pronavirus disease (COVID-19): a living guideline, D August 2023 (55)	WHO	2023	International	Masking	Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences; Asked guideline development to make assumptions about preferences; Consulted authoritative professional assoc Directly engaged lay persons on guideline development group
nfection prevention and control in the context of oronavirus disease (COVID-19): a living guideline, 3 January 2023 (53)	WHO	2023	International	Masking	Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences; Asked guideline development to make assumptions about preferences; Consulted authoritative professional assoc Directly engaged lay persons on guideline development group
nfection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 25 April 2022: updated chapter: mask use, part 1:	WHO	2022	International	Masking	Developing recommendations	Weighing benefits and harms;	Referenced existing research on patients' preferences; Asked guideline development to make assumptions about preferences;

								₹
health care settings (54)						Acceptability	Consulted authoritative professional assoc Directly engaged lay persons on guideline development group	<u> </u>
Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 7 March 2022 (56)	WHO	2022	International	Masking	Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences; Asked guideline development to make assumptions about preferences; Consulted authoritative professional assoc Directly engaged lay persons on guideline development group	nt group ociation e
Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 9 October 2023 (57)	wнo	2023	International	Masking	Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences; Asked guideline development to make assumptions about preferences; Consulted authoritative professional assoc Directly engaged lay persons on guideline development group	nt s made
Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years — United States, July 2022 (82)	CDC	2022	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences	or/fund nder a
Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine (83)	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences	who has gra
Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID- 19: interim guidance, first issued 3 November 2021, updated 15 March 2022 (84)	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences	medRxiv anternation
Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 VaxzevriaTM, SII COVISHIELDTM) (85)	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences	cense to
Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm (86)	WHO	2021	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences	o display the preprint in perpetuity.
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by	WHO	2022	International	Vaccination & vaccine	Recommend for consideration of values & preferences in	Weighing benefits and	Referenced existing research on patients' preferences	erpetuli
							20	ج 0.

Sinovac: interim guidance (87)				prioritization	implementation of recommendations; Developing recommendations	harms; Acceptability	
Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance (88)	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences
Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19: interim guidance, 20 December 2021 "Update coming soon" (89)	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' = 50 preferences
Interim recommendations for use of the Pfizer– BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing (90)	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' ab preferences
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 (91)	CDC	2022	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
Recommendations from the WHO Technical Advisory Group on Safe Schooling During the COVID-19 Pandemic: revised version following the eighth TAG meeting, 20 January 2022 (64)	WHO	2022	International	School & education	Developing recommendations	NR	Directly engage lay persons as part of guidely development group
Schooling during COVID-19: recommendations from the European Technical Advisory Group for schooling during COVID-19, June 2021 (92)	WHO	2021	International	School & education	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Acceptability	Referenced existing research on patients' preferences
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine (65)	CDC	2022	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years—United States, May 2021 (93)	CDC	2021	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged	CDC	2021	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences


5–11 Years (94)							
The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021 (95)	CDC	2021	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged >/=16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021 (96)	CDC	2021	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
CDC: Centers for Disease Control and Prevention WHO: World Health Organization							- 7

Figure 1: Overview of methods and findings



Caption: We searched the eCOVID19 RecMap platform—a comprehensive international catalog of COVID-19 guidelines—for COVID-19 public health guidelines containing one or more recommendations addressing vaccination, masking, isolation, lockdowns, travel restrictions, contact tracing, infection surveillance, and school closures. Reviewers worked independently and in duplicate to assess guidelines for eligibility. From eligible guidelines, reviewers again worked independently and duplicate to collect information on whether and how guidelines considered public values and preferences. Reviewers used a previously established framework by Armstrong and colleagues classify the steps in guideline development in which values and preferences were considered, the purpose for which values and preferences were considered, and the methods used to consider values and preferences.

Figure 2: Selection of guidelines



Caption: We searched the eCOVID19 RecMap platform—a comprehensive international catalog of COVID-19 guidelines—for COVID-19 public health guidelines containing one or more recommendations addressing vaccination, masking, isolation, lockdowns, travel restrictions, contact tracing, infection surveillance, and school closures. We supplemented our search by reviewing webpages of national and international guideline producing organizations (i.e., WHO, US CDC, and European Centers for Disease Control) and reviewing the references of the included guidelines, by which we identified five additional guidelines. Reviewers worked independently and in duplicate to assess guidelines for eligibility. Ultimately, 129 guidelines met eligibility and were included in this study.

References

410

- 411 1. National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National
- 412 Institute for Health and Clinical Excellence; 2007.
- 413 2. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice G. In:
- 414 Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, editors. Clinical Practice Guidelines
- We Can Trust. Washington (DC): National Academies Press (US); 2011.
- 416 3. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing
- guideline development, reporting and evaluation in health care. Cmaj. 2010;182(18):E839-42.
- 418 4. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees P. Guidelines
- International Network: toward international standards for clinical practice guidelines. Ann Intern Med.
- 420 2012;156(7):525-31.
- 421 5. Schünemann HJ, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R, et al. Guidelines
- 422 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. Cmaj.
- 423 2014;186(3):E123-42.
- 424 6. Guyatt GH, Sinclair J, Cook DJ, Glasziou P, for the Evidence-Based Medicine Working Group and
- the Cochrane Applicability Methods Working Group. Users' guides to the medical literature: XVI. How to
- use a treatment recommendation. JAMA 1999;281:1836e43.
- 427 7. Guyatt GH, Haynes RB, Jaeschke RZ, Cook DJ, Green L, Naylor CD, et al. Users' guides to the
- medical literature: XXV. Evidence-based medicine: principles for applying the users' guides to patient
- 429 care. JAMA 2000;284:1290e6.
- 430 8. Bouvy JC, Cowie L, Lovett R, Morrison D, Livingstone H, Crabb N. Use of patient preference
- 431 studies in HTA decision making: a NICE perspective. Patient 2020;13:145e9.
- 432 9. Cochrane Cochrane consumer engagement and involvement framework to 2027.
- 433 https://consumers.cochrane.org/sites/consumers.

cochrane.org/files/uploads/inline-

- 434 files/Cochrane%20consumer%
- 20engagement%20and%20involvement%20framework%20to%

- 435 202027 1.pdf.
- 436 10. Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al.
- 437 GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well
- informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.
- 439 11. Zeng L, Helsingen LM, Bretthauer M, Agoritsas T, Vandvik PO, Mustafa RA, et al. A novel
- 440 framework for incorporating patient values and preferences in making guideline recommendations:
- 441 guideline panel surveys. J Clin Epidemiol. 2023.
- 442 12. Légaré F, Boivin A, van der Weijden T, Pakenham C, Burgers J, Légaré J, et al. Patient and public
- 443 involvement in clinical practice guidelines: a knowledge synthesis of existing programs. Med Decis
- 444 Making. 2011;31(6):E45-74.
- 445 13. Sacristán JA, Aguarón A, Avendaño-Solá C, Garrido P, Carrión J, Gutiérrez A, et al. Patient
- involvement in clinical research: why, when, and how. Patient Prefer Adherence. 2016;10:631-40.
- 447 14. Armstrong MJ, Mullins CD, Gronseth GS, Gagliardi AR. Impact of patient involvement on clinical
- practice guideline development: a parallel group study. Implementation Science. 2018;13(1):55.
- 449 15. Schünemann HJ, Wiercioch W, Brozek J, Etxeandia-lkobaltzeta I, Mustafa RA, Manja V, et al.
- 450 GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of
- 451 trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-10.
- 452 16. World Health O. WHO handbook for guideline development. 2nd ed. Geneva: World Health
- 453 Organization; 2014 2014.
- 454 17. Biddle MSY, Gibson A, Evans D. Attitudes and approaches to patient and public involvement
- across Europe: A systematic review. Health Soc Care Community. 2021;29(1):18-27.

- 456 18. Armstrong MJ, Rueda JD, Gronseth GS, Mullins CD. Framework for enhancing clinical practice
- 457 guidelines through continuous patient engagement. Health Expect. 2017;20(1):3-10.
- 458 19. Zhang Y, Coello PA, Brożek J, Wiercioch W, Etxeandia-Ikobaltzeta I, Akl EA, et al. Using patient
- values and preferences to inform the importance of health outcomes in practice guideline development
- 460 following the GRADE approach. Health Qual Life Outcomes. 2017;15(1):52.
- 461 20. Kim C, Armstrong MJ, Berta WB, Gagliardi AR. How to identify, incorporate and report patient
- preferences in clinical guidelines: A scoping review. Health Expect. 2020;23(5):1028-36.
- 463 21. Kim C, Berta WB, Gagliardi AR. Exploring approaches to identify, incorporate and report patient
- preferences in clinical guidelines: Qualitative interviews with guideline developers. Patient Educ Couns.
- 465 2021;104(4):703-8.
- 466 22. Selva A, Sanabria AJ, Pequeño S, Zhang Y, Solà I, Pardo-Hernandez H, et al. Incorporating
- patients' views in guideline development: a systematic review of guidance documents. Journal of Clinical
- 468 Epidemiology. 2017;88:102-12.
- 469 23. Zhang Y, Alonso-Coello P, Guyatt GH, Yepes-Nuñez JJ, Akl EA, Hazlewood G, et al. GRADE
- 470 Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and
- preferences-Risk of bias and indirectness. J Clin Epidemiol. 2019;111:94-104.
- 24. Zhang Y, Coello PA, Guyatt GH, Yepes-Nuñez JJ, Akl EA, Hazlewood G, et al. GRADE guidelines:
- 473 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences-
- inconsistency, imprecision, and other domains. J Clin Epidemiol. 2019;111:83-93.
- 475 25. Zheng Q, Jones FK, Leavitt SV, Ung L, Labrique AB, Peters DH, et al. HIT-COVID, a global database
- tracking public health interventions to COVID-19. Scientific Data. 2020;7(1):286.
- 477 26. Wang D, Mao Z. A comparative study of public health and social measures of COVID-19
- advocated in different countries. Health Policy. 2021;125(8):957-71.
- 479 27. Fouda A, Mahmoudi N, Moy N, Paolucci F. The COVID-19 pandemic in Greece, Iceland, New
- 480 Zealand, and Singapore: Health policies and lessons learned. Health Policy and Technology.
- 481 2020;9(4):510-24.
- 482 28. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of
- 483 non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257-61.
- 484 29. Richards T, Scowcroft H. Patient and public involvement in covid-19 policy making. BMJ.
- 485 2020;370:m2575.
- 486 30. Casassus B. Covid-19: French sidelining of patient associations is a global trend. Bmj.
- 487 2020;371:m4082.
- 488 31. Mouter N, Hernandez JI, Itten AV. Public participation in crisis policymaking. How 30,000 Dutch
- 489 citizens advised their government on relaxing COVID-19 lockdown measures. PLOS ONE.
- 490 2021;16(5):e0250614.
- 491 32. Dostal JM. Governing Under Pressure: German Policy Making During the Coronavirus Crisis. Polit
- 492 Q. 2020;91(3):542-52.
- 493 33. Schünemann HJ, Santesso N, Vist GE, Cuello C, Lotfi T, Flottorp S, et al. Using GRADE in situations
- of emergencies and urgencies: certainty in evidence and recommendations matters during the COVID-19
- 495 pandemic, now more than ever and no matter what. J Clin Epidemiol. 2020;127:202-7.
- 496 34. Schoch-Spana M, Franco C, Nuzzo JB, Usenza C. Community engagement: leadership tool for
- catastrophic health events. Biosecur Bioterror. 2007;5(1):8-25.
- 498 35. Dyer O. Covid-19: Ottawa declares emergency as truckers' protest continues. Bmj.
- 499 2022;376:o352.
- 500 36. Paterlini M. Covid-19: Italy sees protests against mandatory health passports for workplaces.
- 501 Bmj. 2021;375:n2575.
- 502 37. Druml C, Czech H. A pandemic is no private matter: the COVID-19 vaccine mandate in Austria.
- 503 Lancet Respir Med. 2022;10(4):322-4.

- 504 38. Ward JK, Gauna F, Gagneux-Brunon A, Botelho-Nevers E, Cracowski JL, Khouri C, et al. The
- French health pass holds lessons for mandatory COVID-19 vaccination. Nat Med. 2022;28(2):232-5.
- 506 39. Sleath B, Carpenter DM, Slota C, Williams D, Tudor G, Yeatts K, et al. Communication during
- pediatric asthma visits and self-reported asthma medication adherence. Pediatrics. 2012;130(4):627-33.
- 508 40. Cronin RM, Mayo-Gamble TL, Stimpson SJ, Badawy SM, Crosby LE, Byrd J, et al. Adapting medical
- guidelines to be patient-centered using a patient-driven process for individuals with sickle cell disease
- and their caregivers. BMC Hematol. 2018;18:12.
- 511 41. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020
- 512 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.
- 513 42. Nasir ZH, Mertz D, Nieuwlaat R, Santesso N, Lotfi T, Motilall A, et al. An evaluation of the COVID-
- 514 19 recommendation map identified diverging clinical and public health guidance. J Clin Epidemiol.
- 515 2022;147:83-94.
- 516 43. Lotfi T, Stevens A, Akl EA, Falavigna M, Kredo T, Mathew JL, et al. Getting trustworthy guidelines
- 517 into the hands of decision-makers and supporting their consideration of contextual factors for
- 518 implementation globally: recommendation mapping of COVID-19 guidelines. J Clin Epidemiol.
- 519 2021;135:182-6.
- 520 44. Dewidar O, Lotfi T, Langendam MW, Parmelli E, Saz Parkinson Z, Solo K, et al. Good or best
- practice statements: proposal for the operationalisation and implementation of GRADE guidance. BMJ
- 522 Evid Based Med. 2023;28(3):189-96.
- 523 45. Guyatt GH, Alonso-Coello P, Schünemann HJ, Djulbegovic B, Nothacker M, Lange S, et al.
- 524 Guideline panels should seldom make good practice statements: guidance from the GRADE Working
- 525 Group. J Clin Epidemiol. 2016;80:3-7.
- 526 46. Bardosh K, Krug A, Jamrozik E, Lemmens T, Keshavjee S, Prasad V, et al. COVID-19 vaccine
- 527 boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at
- 528 universities. J Med Ethics. 2022.
- 529 47. Allen DW. Covid-19 Lockdown Cost/Benefits: A Critical Assessment of the Literature.
- International Journal of the Economics of Business. 2022;29(1):1-32.
- 531 48. Miles DK, Stedman M, Heald AH. "Stay at Home, Protect the National Health Service, Save
- 532 Lives": A cost benefit analysis of the lockdown in the United Kingdom. Int J Clin Pract.
- 533 2021;75(3):e13674.
- 534 49. Silverman M, Sibbald R, Stranges S. Ethics of COVID-19-related school closures. Can J Public
- 535 Health. 2020;111(4):462-5.
- 536 50. Christakis DA, Van Cleve W, Zimmerman FJ. Estimation of US Children's Educational Attainment
- and Years of Life Lost Associated With Primary School Closures During the Coronavirus Disease 2019
- 538 Pandemic. JAMA Netw Open. 2020;3(11):e2028786.
- 539 51. lenca M, Vayena E. On the responsible use of digital data to tackle the COVID-19 pandemic. Nat
- 540 Med. 2020;26(4):463-4.
- 541 52. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging
- consensus on rating quality of evidence and strength of recommendations. Bmj. 2008;336(7650):924-6.
- 543 53. World Health Organization (WHO) Infection prevention and control in the context of coronavirus
- disease (COVID-19): a living guideline, 13 January 2023. January 2023.
- 545 54. World Health Organization (WHO) Infection prevention and control in the context of coronavirus
- disease (COVID-19): a living guideline, 25 April 2022: updated chapter: mask use, part 1: health care
- 547 settings. April 2022.
- 548 55. World Health Organization (WHO) Infection prevention and control in the context of coronavirus
- disease (COVID-19): a living guideline, 10 August 2023. August 2023.
- 550 56. World Health Organization (WHO) Infection prevention and control in the context of coronavirus
- disease (COVID-19): a living guideline, 7 March 2022. March 2022.

- 552 57. World Health Organization (WHO) Infection prevention and control in the context of coronavirus
- disease (COVID-19): a living guideline, 9 October 2023. October 2023
- 554 58. World Health Organization (WHO) Guideline WHO Infection Prevention and Control COVID-19
- Living Guideline Mask use in community settings. December 2021.
- 556 59. Mickells GE, Figueroa J, West KW, Wood A, McElhanon BO. Adherence to Masking Requirement
- 557 During the COVID-19 Pandemic by Early Elementary School Children. J Sch Health. 2021;91(7):555-61.
- 558 60. Aronu AE, Chinawa JM, Nduagubam OC, Ossai EN, Chinawa AT, Igwe WC. Maternal perception
- of masking in children as a preventive strategy for COVID-19 in Nigeria: A multicentre study. PLoS One.
- 560 2020;15(11):e0242650.
- 561 61. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of
- pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav. 2021;5(4):529-38.
- 563 62. Face masks and coverings for the general public: Behavioural knowledge, effectiveness of cloth
- coverings and public messaging. The Royal Society. 2020.
- 565 63. Tsang PM, Prost A. Boundaries of solidarity: a meta-ethnography of mask use during past epidemics to inform SARS-CoV-2 suppression. BMJ Glob Health. 2021;6(1).
- 567 64. World Health Organization (WHO) Recommendations from the WHO Technical Advisory Group
- on Safe Schooling During the COVID-19 Pandemic: revised version following the eighth TAG meeting, 20 January 2022. January 2022.
- 570 65. Wallace M, Moulia D, Blain AE, Ricketts EK, Minhaj FS, Link-Gelles R, et al. The Advisory
- 571 Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in
- 572 Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series
- 573 Doses of mRNA COVID-19 Vaccines United States, February 2022. Centers for Disease Control and
- 574 Prevention (CDC). February 2022;71(11):416-21.
- 575 66. Blackwood J, Armstrong MJ, Schaefer C, Graham ID, Knaapen L, Straus SE, et al. How do
- 576 guideline developers identify, incorporate and report patient preferences? An international cross-
- sectional survey. BMC Health Serv Res. 2020;20(1):458.
- 578 67. Levitt EE, Gohari MR, Syan SK, Belisario K, Gillard J, DeJesus J, et al. Public health guideline
- 579 compliance and perceived government effectiveness during the COVID-19 pandemic in Canada: Findings
- from a longitudinal cohort study. Lancet Reg Health Am. 2022;9:100185.
- 581 68. Sabat I, Neumann-Böhme S, Varghese NE, Barros PP, Brouwer W, van Exel J, et al. United but
- divided: Policy responses and people's perceptions in the EU during the COVID-19 outbreak. Health
- 583 Policy. 2020;124(9):909-18.
- 584 69. Moran C, Campbell DJT, Campbell TS, Roach P, Bourassa L, Collins Z, et al. Predictors of attitudes
- and adherence to COVID-19 public health guidelines in Western countries: a rapid review of the
- emerging literature. J Public Health (Oxf). 2021;43(4):739-53.
- 587 70. Betsch C, Korn L, Felgendreff L, Eitze S, Thaiss H. School opening during the SARS-CoV-2
- pandemic: Public acceptance of wearing fabric masks in class. Public Health Pract (Oxf). 2021;2:100115.
- 589 71. Dewidar O, Bondok M, Abdelrazeq L, Aliyeva K, Solo K, Welch V, et al. Equity issues rarely
- addressed in the development of COVID-19 formal recommendations and good practice statements: a
- cross-sectional study. J Clin Epidemiol. 2023;161:116-26.
- 592 72. Tripp L, Vanstone M, Canfield C, Leslie M, Levasseur MA, Panday J, et al. The impact of COVID-19
- on patient engagement in the health system: Results from a Pan-Canadian survey of patient, family and
- caregiver partners. Health Expect. 2022;25(2):744-53.
- 595 73. Webster N. Public discussions on COVID-19 lockdown in Scotland 2020 [Available from:
- 596 https://medium.com/participo/public-discussions-on-covid-19-lockdown-in-scotland-8f34a586c69c.
- 597 74. Emanuel EJ, Upshur REG, Smith MJ. What Covid Has Taught the World about Ethics. N Engl J
- 598 Med. 2022;387(17):1542-5.
- 599 75. Parasidis E, Fairchild AL. Closing the Public Health Ethics Gap. N Engl J Med. 2022;387(11):961-3.

- 600 76. Jamrozik E. Public health ethics: critiques of the "new normal". Monash Bioethics Review.
- 601 2022;40(1):1-16.
- 602 77. Cox, Daniel A., Anthony M. Mills, lan R. Banks, Kelsey Eyre Hammond, and Kyle Gray.
- 603 2023. "America's Crisis of Confidence: Rising Mistrust, Conspiracies, and Vaccine Hesitancy After COVID-
- 19." The Survey Center on American Life (blog). 2023.
- 605 78. National Institute for Health Care E. NICE Process and Methods Guides. Developing NICE
- 606 Guidelines: The Manual. London: National Institute for Health and Care Excellence (NICE); 2015.
- 607 79. Fleming-Dutra KE, Wallace M, Moulia DL, Twentyman E, Roper LE, Hall E, et al. Interim
- Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and
- 609 Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years United States, June 2022.
- 610 Centers for Disease Control and Prevention (CDC). June 2022;71(26):859-68.
- 611 80. World Health Organization (WHO) COVID-19 immunization in refugees and migrants: principles
- and key considerations: interim guidance, 31 August 2021. August 2021.
- 613 81. American College of Obstetricians and Gynecologists (ACOG) COVID-19 Vaccination
- 614 Considerations for Obstetric–Gynecologic Care. May 2023.
- 615 82. Twentyman E, Wallace M, Roper LE, Anderson TC, Rubis AB, Fleming-Dutra KE, et al. Interim
- 616 Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-
- 617 19 Vaccine in Persons Aged ≥18 years United States, July 2022. Centers for Disease Control and
- 618 Prevention (CDC). August 2022;71(31):988-92.
- 619 83. World Health Organization (WHO) Interim recommendations for the use of the Janssen
- 620 Ad26.COV2.S (COVID-19) vaccine. June 2022.
- 621 84. World Health Organization (WHO) Interim recommendations for use of the Bharat Biotech
- BBV152 COVAXIN® vaccine against COVID-19: interim guidance, first issued 3 November 2021, updated
- 623 15 March 2022. March 2022.
- 624 85. World Health Organization (WHO) Interim recommendations for use of the ChAdOx1-S
- 625 [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII
- 626 COVISHIELD™). March 2022.
- 627 86. World Health Organization (WHO) Interim recommendations for use of the inactivated COVID-19
- 628 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm. May 2021.
- 629 87. World Health Organization (WHO) Interim recommendations for use of the inactivated COVID-
- 630 19 vaccine, CoronaVac, developed by Sinovac. March 2022.
- 631 88. World Health Organization (WHO) Interim recommendations for use of the Moderna mRNA-
- 632 1273 vaccine against COVID-19. August 2022.
- 633 89. World Health Organization (WHO) Interim recommendations for use of the Novavax
- 634 NVXCoV2373 vaccine against COVID-19. September 2022.
- 635 90. World Health Organization (WHO) Interim recommendations for use of the Pfizer–BioNTech
- 636 COVID-19 vaccine, BNT162b2, under Emergency Use Listing. January 2022.
- 637 91. Rosenblum HG, Wallace M, Godfrey M, Roper LE, Hall E, Fleming-Dutra KE, et al. Interim
- 638 Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent
- 639 Booster Doses of COVID-19 Vaccines United States, October 2022. Centers for Disease Control and
- Prevention (CDC). November 2022;71(45):1436-41.
- 641 92. World Health Organization (WHO) Schooling during COVID-19: recommendations from the
- 642 European Technical Advisory Group for schooling during COVID-19, June 2021. June 2021.
- 643 93. Wallace M, Woodworth KR, Gargano JW, Scobie HM, Blain AE, Moulia D, et al. The Advisory
- 644 Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19
- 645 Vaccine in Adolescents Aged 12–15 Years United States, May 2021. Centers for Disease Control and
- 646 Prevention (CDC). May 2021;70(20):749-52.

- 647 94. Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, et al. The Advisory
- 648 Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19
- Vaccine in Children Aged 5–11 Years United States, November 2021. Centers for Disease Control and
- 650 Prevention (CDC). November 2021;70(45):1579-83.
- 651 95. Mbaeyi S OS, Collins JP, Godfrey M, Goswami ND, Hadler SC, Jones J, Moline H, Moulia D, Reddy
- 652 S, Schmit K, Wallace M, Chamberland M, Campos-Outcalt D, Morgan RL, Bell BP, Brooks O, Kotton C,
- Talbot HK, Lee G, Daley MF, Dooling K. The Advisory Committee on Immunization Practices' Interim
- Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines United States,
- 655 2021. Centers for Disease Control and Prevention (CDC). November 2021;70.
- 656 96. Dooling K, Gargano JW, Moulia D, Wallace M, Rosenblum HG, Blain AE, et al. Use of Pfizer-
- 657 BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee
- 658 on Immunization Practices United States, September 2021. Centers for Disease Control and
- 659 Prevention (CDC). September 2021;70(38):1344-8.